biotickrAdamis Pharmaceuticals Corp
The 0A4X-LN stock trades on London Stock Exchange
Company Description
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products in various therapeutic areas, including respiratory disease, allergy and opioid overdose.
The mission of Adamis is to provide high quality, affordable alternatives to existing therapies in various therapeutic areas to reach a broader range of patients.
The mission of Adamis is to provide high quality, affordable alternatives to existing therapies in various therapeutic areas to reach a broader range of patients.
Drug Pipeline
Source: Adamis Pharmaceuticals Corp - 20220902
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
APC-400
Respiratory Disease
Phase 2
APC-410
Radiation Dermatitis
Phase 2
SYMJEPI
Anaphylaxis
Reg/Com
ZIMHI
Opioid Overdose
Reg/Com
0 Comments on 0A4X-LN stock
Newest
Trialfinder
betaTerminatedStudy to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
Unknown Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
WithdrawnBeclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
Conversation